ERBB2 and breast cancer: Recently, the new generation of HER2‐directed antibody–drug conjugates, particularly trastuzumab deruxtecan, have shown substantial efficacy in HER2‐low BC, suggesting a possibility of improving the clinical interpretation of HER2 status from the current binary to a ternary pattern.3